JP2008102129A - 急性肺塞栓症用生化学マーカー - Google Patents
急性肺塞栓症用生化学マーカー Download PDFInfo
- Publication number
- JP2008102129A JP2008102129A JP2007239009A JP2007239009A JP2008102129A JP 2008102129 A JP2008102129 A JP 2008102129A JP 2007239009 A JP2007239009 A JP 2007239009A JP 2007239009 A JP2007239009 A JP 2007239009A JP 2008102129 A JP2008102129 A JP 2008102129A
- Authority
- JP
- Japan
- Prior art keywords
- amount
- pulmonary embolism
- proanp
- hours
- probnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010378 Pulmonary Embolism Diseases 0.000 title claims abstract description 105
- 230000001154 acute effect Effects 0.000 title claims abstract description 48
- 239000003150 biochemical marker Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 81
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims abstract description 66
- 102400001263 NT-proBNP Human genes 0.000 claims abstract 14
- 238000011282 treatment Methods 0.000 claims description 11
- 238000003745 diagnosis Methods 0.000 claims description 10
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229960000103 thrombolytic agent Drugs 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000002537 thrombolytic effect Effects 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 82
- 102000004196 processed proteins & peptides Human genes 0.000 description 60
- 229920001184 polypeptide Polymers 0.000 description 54
- 239000003446 ligand Substances 0.000 description 45
- 239000000523 sample Substances 0.000 description 37
- 238000005259 measurement Methods 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 230000027455 binding Effects 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 101500026734 Homo sapiens NT-proBNP Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000003748 differential diagnosis Methods 0.000 description 4
- 230000010102 embolization Effects 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108020001621 Natriuretic Peptide Proteins 0.000 description 3
- 102000004571 Natriuretic peptide Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000692 natriuretic peptide Substances 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 210000005241 right ventricle Anatomy 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 102100034296 Natriuretic peptides A Human genes 0.000 description 2
- 101710187800 Natriuretic peptides A Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 2
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000004848 nephelometry Methods 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- HJCUTNIGJHJGCF-UHFFFAOYSA-N 9,10-dihydroacridine Chemical class C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500027325 Homo sapiens Atrial natriuretic peptide Proteins 0.000 description 1
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101500028867 Homo sapiens Neurotensin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000014731 pulmonary artery disease Diseases 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
【解決手段】急性肺塞栓症の罹患が疑われる被験体のサンプル中のNT-proBNP量を測定するステップと、その量を参照量と比較するステップとを含む方法を実施するのに適した装置およびキットを使用することによって、急性肺塞栓症の罹患が疑われる被験体における単一性肺塞栓症と多発性肺塞栓症を鑑別する。さらに、第1時点と第2時点のNT-proANP量を測定するステップと、測定した量を相互に比較するステップを含む方法を実施するのに適した装置およびキットを使用することによって、被験体における急性肺塞栓症と慢性肺塞栓症とを鑑別する。
【選択図】なし
Description
a) 急性肺塞栓症の罹患が疑われる被験体のサンプル中のNT-proBNP量を測定するステップ;および
b) ステップa)で測定した量を参照量と比較するステップであって、これにより参照量に満たない量は単一性肺塞栓症を示し、参照量を上回る量は多発性肺塞栓症を示す、該ステップ、
を含んでなる、前記方法に関する。
c) 前記サンプル中のNT-proANP量を、ステップa)のNT-proBNP量と同時に測定するステップ;
d) 一定時間後の時点で採取した前記被験体のさらなるサンプル中のNT-proANP量を測定するステップ;
e) ステップd)で測定したNT-proANP量をステップc)で測定したNT-proANP量と比較するステップであって、ここでNT-proANPの減少は急性肺塞栓症を示す、ステップ、
をさらに含む。
a) 肺塞栓症を患う被験体の、第1時点のサンプル中のNT-proANP量を測定するステップ;
b) 肺塞栓症を患う被験体の、一定時間後の第2時点のサンプル中のNT-proANP量を測定するステップ;および
c) ステップa)で測定したNT-proANP量をステップb)で測定したNT-proANP量と比較するステップであって、ここでNT-proANPの減少は急性肺塞栓症を示す、該ステップ、
を含んでなる、上記方法も包含するものとなる。
本発明の方法の好ましい実施形態において、前記方法はさらに、ステップa)とステップb)においてNT-proBNP量を、NT-proANP量と共に同時に測定するステップと、ステップa)のNT-proBNP量をステップb)で測定したNT-proBNP量と比較するステップであって、ここでNT-proBNPの増加は急性肺塞栓症をさらに示す、該ステップ、を含んでなる。
a) NT-proANP量の測定手段;
b) NT-proBNP量の測定手段;および/または
c) NT-proANP量同士およびNT-proBNP量同士の比較手段
を含んでなる、本発明の方法の実施に適した装置にも関する。
a) NT-proANP量の測定手段;
b) NT-proBNP量の測定手段;および/または
c) NT-proANP量同士およびNT-proBNP量同士の比較手段;および
d) 上記方法を実施するための使用説明書
を含む、本発明の方法を実施するためのキットに関する。
本研究には、肺塞栓症の罹患が疑われる計34人の患者を含めた。患者は全員、緊急治療室に現れた後4時間以内にCTスキャンを受けた。
Claims (17)
- 急性肺塞栓症の罹患が疑われる被験体における単一性肺塞栓症と多発性肺塞栓症とを鑑別する方法であって、
a) 急性肺塞栓症の罹患が疑われる被験体のサンプル中のNT-proBNP量を測定するステップ;および
b) ステップa)で測定した量を参照量と比較するステップであって、これにより参照量に満たない量は単一性肺塞栓症を示し、参照量を上回る量は多発性肺塞栓症を示す、該ステップ、
を含んでなる、前記方法。 - 参照量が、NT-proBNPの正常値上限(ULN)の6〜12倍の間である、請求項1に記載の方法。
- 正常値上限(ULN)が125 pg/mlである、請求項2に記載の方法。
- 参照量が1000 pg/mlである、請求項1〜3のいずれか1項に記載の方法。
- 以下のステップ:
c) サンプル中のNT-proANP量を、ステップa)のNT-proBNP量と同時に測定するステップ;
d) 一定時間後の時点で採取された前記被験体のさらなるサンプル中のNT-proANP量を、測定するステップ;
e) ステップd)で測定したNT-proANP量をステップc)で測定したNT-proANP量と比較するステップであって、ここでNT-proANPの減少は急性肺塞栓症を示す、該ステップ、
をさらに含む、請求項1〜4のいずれか1項に記載の方法。 - 一定時間が、少なくとも2時間、4時間、5時間、6時間、7時間、8時間、9時間、10時間、11時間または12時間である、請求項5に記載の方法。
- 肺塞栓症を患う被験体における急性肺塞栓症と慢性肺塞栓症とを鑑別する方法であって、
a) 肺塞栓症を患う被験体の、第1時点のサンプル中のNT-proANP量を測定するステップ;
b) 肺塞栓症を患う被験体の、一定時間後の第2時点のサンプル中のNT-proANP量を測定するステップ;および
c) ステップa)で測定したNT-proANP量をステップb)で測定したNT-proANP量と比較するステップであって、ここでNT-proANPの減少は急性肺塞栓症を示す、該ステップ、
を含んでなる、前記方法。 - 一定時間が、少なくとも2時間、4時間、5時間、6時間、7時間、8時間、9時間、10時間、11時間または12時間である、請求項7に記載の方法。
- ステップa)とステップb)においてNT-proBNP量をNT-proANP量と共に同時に測定し、ステップa)のNT-proBNP量をステップb)で測定したNT-proBNP量と比較するステップであって、ここでNT-proBNPの増加は急性肺塞栓症を示す、該ステップ、をさらに含んでなる、請求項7または8に記載の方法。
- サンプルが血液、血清または血漿である、請求項1〜9のいずれか1項に記載の方法。
- 被験体がヒトである、請求項1〜10のいずれか1項に記載の方法。
- 肺塞栓症に対する適切な治療法を選択する方法であって、請求項1〜11のいずれか1項に記載の方法のステップ、および前記方法によって得られた診断に基づく適切な治療法を選択するさらなるステップを含んでなる、前記方法。
- 前記診断が単一性肺塞栓症および/または急性肺塞栓症である場合、適切な治療法が血栓溶解作用剤による血栓溶解である、請求項12に記載の方法。
- 前記診断が多発性肺塞栓症である場合、適切な治療法が外科手術による血栓の除去である、請求項12に記載の方法。
- 請求項1〜14のいずれか1項に記載の方法の実施に適した装置であって、
a) NT-proANP量の測定手段;
b) NT-proBNP量の測定手段;および
c) NT-proANP量同士及びNT-proBNP量同士の比較手段
を含んでなる、前記装置。 - 急性肺塞栓症と慢性肺塞栓症とを鑑別するための診断用組成物の製造のための、(i)NT-proANPおよびNT-proBNP、または(ii)NT-proANPの測定手段およびNT-proBNPの測定手段の、使用。
- 請求項1〜14のいずれか1項に記載の方法の実施に適したキットであって、
a) NT-proANP量の測定手段;
b) NT-proBNP量の測定手段;
c) NT-proANP量同士およびNT-proBNP量同士の比較手段;および
d) 前記方法を実施するための使用説明書
を含んでなる、前記キット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06120782.5 | 2006-09-15 | ||
EP06120782A EP1901072B1 (en) | 2006-09-15 | 2006-09-15 | Biochemical markers for acute pulmonary embolism |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008102129A true JP2008102129A (ja) | 2008-05-01 |
JP4689651B2 JP4689651B2 (ja) | 2011-05-25 |
Family
ID=37908012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007239009A Active JP4689651B2 (ja) | 2006-09-15 | 2007-09-14 | 急性肺塞栓症用生化学マーカー |
Country Status (8)
Country | Link |
---|---|
US (3) | US7651679B2 (ja) |
EP (1) | EP1901072B1 (ja) |
JP (1) | JP4689651B2 (ja) |
CN (1) | CN101144811A (ja) |
AT (1) | ATE449966T1 (ja) |
CA (1) | CA2601147A1 (ja) |
DE (1) | DE602006010705D1 (ja) |
ES (1) | ES2334155T3 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013510289A (ja) * | 2009-11-03 | 2013-03-21 | エフ.ホフマン−ラ ロシュ アーゲー | 循環系事象と虚血性事象を鑑別するためのNT−proANPおよびSFlt−1 |
JP2015504519A (ja) * | 2011-12-01 | 2015-02-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 脳卒中診断のためのNT−proANP及びNT−proBNP |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
CN104937418B (zh) * | 2012-11-15 | 2019-08-23 | 奥索临床诊断有限公司 | 使用反应时间的校准分析 |
CN109652525A (zh) * | 2018-11-30 | 2019-04-19 | 深圳市人民医院 | 肺血栓栓塞症基因面板试剂盒及其应用 |
US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
WO2006087373A1 (en) * | 2005-02-17 | 2006-08-24 | F. Hoffmann-La Roche Ag | Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
ATE458199T1 (de) | 2001-05-04 | 2010-03-15 | Biosite Inc | Diagnostische marker der akuten koronaren syndrome und ihre verwendungen |
GB2403533A (en) * | 2003-06-30 | 2005-01-05 | Orion Corp | Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof |
DE102005016369A1 (de) | 2005-04-09 | 2006-10-12 | Degussa Ag | Verfahren zur kontinuierlichen Herstellung von Methylmercaptan |
-
2006
- 2006-09-15 DE DE602006010705T patent/DE602006010705D1/de active Active
- 2006-09-15 EP EP06120782A patent/EP1901072B1/en active Active
- 2006-09-15 AT AT06120782T patent/ATE449966T1/de active
- 2006-09-15 ES ES06120782T patent/ES2334155T3/es active Active
-
2007
- 2007-09-04 US US11/849,407 patent/US7651679B2/en active Active
- 2007-09-11 CA CA002601147A patent/CA2601147A1/en not_active Abandoned
- 2007-09-14 CN CNA2007101536849A patent/CN101144811A/zh active Pending
- 2007-09-14 JP JP2007239009A patent/JP4689651B2/ja active Active
-
2009
- 2009-12-07 US US12/632,026 patent/US8497095B2/en active Active
- 2009-12-07 US US12/631,926 patent/US8501155B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004059293A2 (en) * | 2002-12-24 | 2004-07-15 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
WO2006087373A1 (en) * | 2005-02-17 | 2006-08-24 | F. Hoffmann-La Roche Ag | Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013510289A (ja) * | 2009-11-03 | 2013-03-21 | エフ.ホフマン−ラ ロシュ アーゲー | 循環系事象と虚血性事象を鑑別するためのNT−proANPおよびSFlt−1 |
JP2015504519A (ja) * | 2011-12-01 | 2015-02-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 脳卒中診断のためのNT−proANP及びNT−proBNP |
Also Published As
Publication number | Publication date |
---|---|
DE602006010705D1 (de) | 2010-01-07 |
US20090081719A1 (en) | 2009-03-26 |
ES2334155T3 (es) | 2010-03-05 |
CN101144811A (zh) | 2008-03-19 |
JP4689651B2 (ja) | 2011-05-25 |
US20100081164A1 (en) | 2010-04-01 |
US8501155B2 (en) | 2013-08-06 |
EP1901072B1 (en) | 2009-11-25 |
US20100203571A1 (en) | 2010-08-12 |
US7651679B2 (en) | 2010-01-26 |
CA2601147A1 (en) | 2008-03-15 |
US8497095B2 (en) | 2013-07-30 |
EP1901072A1 (en) | 2008-03-19 |
ATE449966T1 (de) | 2009-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4823170B2 (ja) | 進行型冠動脈疾患およびその合併症のインジケーターとしての心筋トロポニン | |
JP4731525B2 (ja) | 心因性と肺因性の急性呼吸窮迫を鑑別する手段と方法 | |
JP4944185B2 (ja) | 症状のある患者における急性および慢性の心筋壊死の区別のための手段と方法 | |
JP4927825B2 (ja) | 初期段階の心機能異常を診断または予測するための装置および方法 | |
JP5015318B2 (ja) | Gdf−15及びナトリウム利尿ペプチドを用いた、心房細動を有する患者の心不全を評価するための手段及び方法 | |
JP4689651B2 (ja) | 急性肺塞栓症用生化学マーカー | |
JP2011523051A (ja) | 1型糖尿病におけるバイオマーカーとしてのgdf−15 | |
JP5719379B2 (ja) | 心臓手術患者における腎不全を予測するためのgdf−15 | |
JP2011530705A (ja) | 肺塞栓症のためのDダイマー、トロポニン、NT−proBNP | |
JP2011509403A (ja) | Gdf−15に基づいて救急室を受診する患者のリスクを評価するための手段及び方法 | |
JP2020034564A (ja) | 心不全リスクの予測改善のためのバイオマーカー | |
JP5198565B2 (ja) | 心疾患に関連する又は関連しないgdf−15の上昇の区別のための手段及び方法 | |
JP2010539449A (ja) | 右心不全の異なる病因の鑑別 | |
JP4664939B2 (ja) | 息切れの心臓原因および肺原因を鑑別するための手段および方法 | |
JP2010537212A (ja) | 息切れの原因の鑑別におけるサーファクタントプロテインb及びd | |
JP2011524533A (ja) | 炎症バイオマーカーを用いて動脈硬化性狭窄を決定する手段及び方法 | |
JP5369118B2 (ja) | バイオマーカーplgfを用いてアテローム性動脈硬化負荷を決定する手段及び方法 | |
JP5307141B2 (ja) | 心筋梗塞の早期予測因子としてのミオグロビン | |
US8440463B2 (en) | Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1 | |
JP2010528306A (ja) | 心筋梗塞の早期予測因子としてのh−fabp | |
US20110081671A1 (en) | Vascular markers in the remodeling of cardiac injury | |
JP2010513891A (ja) | 胎盤成長因子、可溶性flt1及びエンドグリンは、被験体における血管新生状態の予測因子である |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110125 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4689651 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140225 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |